Merck Restricts Purchases of 340B Drugs for 340B Hospitals Effective September 1st, 2021

On August 11, Merck issued a letter announcing its policy to stop “voluntarily” providing 340B discounts to 340B hospitals on drugs dispensed at contract pharmacies unless the hospital provides 340B contract pharmacy claims data through the 340B ESPTM  platform for both Medicaid and non-Medicaid claims.  Merck joins seven other drug manufacturers that have adopted similar policies based on their…

House of Representatives Approves Spanberger-McKinley Amendment Supporting HRSA Action Against Drug Manufacturer

On July 27, the U.S. House of Representatives approved an amendment to the House Appropriations Labor, Health and Human Services legislation that supports agency action against manufacturers that are not honoring contract pharmacy arrangements.  The amendment was approved as part of a funding package for the next fiscal year for many federal departments, including HHS.  The…